Pular para o conteúdo
Merck
Todas as fotos(1)

Key Documents

228M-1

Sigma-Aldrich

BG8, LewisY (F3) Mouse Monoclonal Antibody

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Código UNSPSC:
12352203
NACRES:
NA.41

fonte biológica

mouse

Nível de qualidade

100
500

conjugado

unconjugated

forma do anticorpo

culture supernatant

tipo de produto de anticorpo

primary antibodies

clone

F3, monoclonal

descrição

For In Vitro Diagnostic Use in Select Regions (See Chart)

forma

buffered aqueous solution

reatividade de espécies

human

embalagem

vial of 0.1 mL concentrate (228M-14)
vial of 0.5 mL concentrate (228M-15)
bottle of 1.0 mL predilute (228M-17)
vial of 1.0 mL concentrate (228M-16)
bottle of 7.0 mL predilute (228M-18)

fabricante/nome comercial

Cell Marque™

técnica(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:10-1:50

Isotipo

IgM

controle

adenocarcinoma of lung

Condições de expedição

wet ice

temperatura de armazenamento

2-8°C

visualização

cytoplasmic

Informações sobre genes

human ... F3(2152)

Categorias relacionadas

Descrição geral

Blood group antigens have been examined as potential discriminators between pulmonary adenocarcinoma (PACA) and epithelioid mesothelioma (EM). Lewisy is the only one of these that appears to have some merit. BG8 is raised from the SK-LU-3 lung cancer line and its ability to distinguish between PACA and EM was first reported by Jordon and colleagues in 1989. Three groups have since reported their results. These studies included 231 cases of PACA and 197 cases of EM. Sensitivity and specificity for PACA were both 93%. Yaziji H et al. reported a sensitivity of nonmesothelial antigens for adenocarcinoma as organ dependent, with BG8 performing at 98% in the breast cancer group, and 100% in the lung cancer group. The specificity of the nonmesothelial (non-EM) antigens for adenocarcinoma was 98% for BG8. They concluded using logical regression analysis that a three-antibody immunohistochemical panel including calretinin, BG8, and MOC-31 would provide 96% sensitivity and specificity for distinguishing EM from adenocarcinoma from a variety of sources (lung, ovary, breast, stomach).

Qualidade


IVD
IVD
IVD
RUO

Ligação

BG8 Positive Control Slides, Product No. 228S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

forma física

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Nota de preparo

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Outras notas

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Informações legais

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Não está encontrando o produto certo?  

Experimente o nosso Ferramenta de seleção de produtos.

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

N G Ordóñez
The American journal of surgical pathology, 24(4), 598-606 (2000-04-11)
The distinction between malignant pleural mesotheliomas and adenocarcinomas, particularly those originating in the lung, is a difficult diagnostic problem that can be facilitated by the use of immunohistochemical markers. In this study, the immunoreactivity of thyroid transcription factor-1 (TTF-1), E-cadherin
B Davidson et al.
Virchows Archiv : an international journal of pathology, 435(1), 43-49 (1999-08-04)
The detection of malignant cells in pleural, peritoneal, and pericardial fluids of cancer patients marks the presence of metastatic disease and is associated with a grave prognosis. We evaluated five epithelial markers for the detection of cancer cells in 94
Alberto M Marchevsky et al.
Applied immunohistochemistry & molecular morphology : AIMM, 15(2), 140-144 (2007-05-26)
There are no firmly established guidelines for the use of antibodies in immunohistology as individual tests or panels. Practicing pathologists must rely on information available in individual publications, review articles, books, and internet-based databases to develop diagnostic immunohistochemical algorithms for
Nelson G Ordóñez
The American journal of surgical pathology, 27(8), 1031-1051 (2003-07-29)
A large number of immunohistochemical markers that can facilitate the distinction between epithelioid pleural mesotheliomas and pulmonary peripheral adenocarcinomas have recently become available. The aim of this study is to compare the value of these new markers with others that
J E King et al.
Histopathology, 48(3), 223-232 (2006-01-25)
Immunohistochemistry is frequently employed to aid the distinction between mesothelioma and pulmonary adenocarcinoma metastatic to the pleura, but there is uncertainty as to which antibodies are most useful. We analysed published data in order to establish sensitivity and specificity of

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica